Justin Klee

Co-CEO, Amylyx Pharmaceuticals

Appears in 1 story

Last updated Oct 12, 2026

Stories

Amylyx Phase III success for avexitide sets up FDA filing

New Capabilities

As of October 2026: Overseeing NDA filing and commercialization strategy

Post-bariatric hypoglycemia has no FDA-approved treatment. In August, Amylyx Pharmaceuticals reported that its Phase III LUCIDITY trial showed avexitide cut dangerous hypoglycemic events by 55% versus placebo (p=0.000003).

Updated Oct 12